# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Neutral and maintains $10 price target.
PEAK Phase 3 guidance accelerated with enrollment completion now expected in 3Q 2024
HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $19 price ...
Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $18 price target.
Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of ...
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.
JP Morgan analyst Anupam Rama maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from ...
Citigroup analyst David Lebowitz maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $11 ...